drugset / Trial / NCT05911399

Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency

NCT05911399

Summary

The goal of this program is to provide expanded access (i.e., before marketing authorization) to tiratricol as treatment for patients with monocarboxylate transporter 8 deficiency (MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome \[AHDS\]), who in their Treating Physician's opinion, could benefit from tiratricol and meet the eligibility criteria.

Timeline

Start
Primary completion
Completion

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tiratricol Small molecule 350 ug Oral